Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BLRX NASDAQ:CTXR NASDAQ:ENTO NASDAQ:MBRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLRXBioLineRx$3.04$2.52$2.15▼$7.77$13.23M1.4224,480 shs9,653 shsCTXRCitius Pharmaceuticals$0.69-3.3%$0.80$0.57▼$2.48$15.89M1.05860,895 shs507,596 shsENTOEntero Therapeutics$2.52+0.4%$2.31$0.32▼$5.84$4.00M1.192.80 million shs44,088 shsMBRXMoleculin Biotech$2.49+0.4%$2.34$1.79▼$28.61$13.23M1.74115,143 shs47,943 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLRXBioLineRx+6.29%+15.59%+37.56%-0.98%-6.46%CTXRCitius Pharmaceuticals-1.86%+5.68%-19.57%-10.94%-15.19%ENTOEntero Therapeutics0.00%+12.00%+5.44%-19.49%+137.69%MBRXMoleculin Biotech-0.80%-2.73%+7.33%-40.43%-90.42%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLRXBioLineRx$3.04$2.52$2.15▼$7.77$13.23M1.4224,480 shs9,653 shsCTXRCitius Pharmaceuticals$0.69-3.3%$0.80$0.57▼$2.48$15.89M1.05860,895 shs507,596 shsENTOEntero Therapeutics$2.52+0.4%$2.31$0.32▼$5.84$4.00M1.192.80 million shs44,088 shsMBRXMoleculin Biotech$2.49+0.4%$2.34$1.79▼$28.61$13.23M1.74115,143 shs47,943 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLRXBioLineRx+6.29%+15.59%+37.56%-0.98%-6.46%CTXRCitius Pharmaceuticals-1.86%+5.68%-19.57%-10.94%-15.19%ENTOEntero Therapeutics0.00%+12.00%+5.44%-19.49%+137.69%MBRXMoleculin Biotech-0.80%-2.73%+7.33%-40.43%-90.42%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLRXBioLineRx 2.67Moderate BuyN/AN/ACTXRCitius Pharmaceuticals 2.00Hold$6.00773.36% UpsideENTOEntero Therapeutics 1.00SellN/AN/AMBRXMoleculin Biotech 2.33Hold$22.00783.53% UpsideCurrent Analyst Ratings BreakdownLatest ENTO, MBRX, BLRX, and CTXR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2026MBRXMoleculin Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026BLRXBioLineRx Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/27/2026CTXRCitius Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/24/2026MBRXMoleculin Biotech HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$22.003/11/2026CTXRCitius Pharmaceuticals D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$6.00(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLRXBioLineRx$1.18M11.21N/AN/A$5.36 per share0.57CTXRCitius PharmaceuticalsN/AN/AN/AN/A$4.29 per shareN/AENTOEntero TherapeuticsN/AN/AN/AN/A($2.45) per shareN/AMBRXMoleculin BiotechN/AN/AN/AN/A$4.69 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLRXBioLineRx-$1.17M-$0.17N/AN/AN/A-99.58%-5.61%-2.81%5/26/2026 (Estimated)CTXRCitius Pharmaceuticals-$37.43M-$2.45N/AN/AN/AN/A-49.34%-28.64%5/13/2026 (Estimated)ENTOEntero Therapeutics-$18.06M-$1.69N/AN/AN/AN/A-461.02%-14.72%5/13/2026 (Estimated)MBRXMoleculin Biotech-$33.56M-$32.75N/AN/AN/AN/AN/A-60.88%5/11/2026 (Estimated)Latest ENTO, MBRX, BLRX, and CTXR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/26/2026Q1 2026BLRXBioLineRx-$1.04N/AN/AN/A$0.34 millionN/A5/13/2026Q2 2026CTXRCitius Pharmaceuticals$0.3885N/AN/AN/A$18.79 millionN/A5/11/2026Q1 2026MBRXMoleculin Biotech-$1.69N/AN/AN/AN/AN/A3/24/2026Q4 2025BLRXBioLineRx-$0.50-$0.34+$0.16N/A$0.49 million$0.19 million2/13/2026Q1 2026CTXRCitius PharmaceuticalsN/A-$0.38N/A-$0.38N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBLRXBioLineRxN/AN/AN/AN/AN/ACTXRCitius PharmaceuticalsN/AN/AN/AN/AN/AENTOEntero TherapeuticsN/AN/AN/AN/AN/AMBRXMoleculin BiotechN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLRXBioLineRx0.191.951.78CTXRCitius PharmaceuticalsN/A0.990.40ENTOEntero TherapeuticsN/A2.622.62MBRXMoleculin BiotechN/A1.411.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLRXBioLineRx1.56%CTXRCitius Pharmaceuticals16.88%ENTOEntero Therapeutics12.30%MBRXMoleculin Biotech15.52%Insider OwnershipCompanyInsider OwnershipBLRXBioLineRx1.10%CTXRCitius Pharmaceuticals4.99%ENTOEntero Therapeutics0.75%MBRXMoleculin Biotech1.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBLRXBioLineRx404.35 million4.30 millionOptionableCTXRCitius Pharmaceuticals2022.38 million21.26 millionOptionableENTOEntero Therapeutics91.59 million3.34 millionN/AMBRXMoleculin Biotech205.34 million5.28 millionNot OptionableENTO, MBRX, BLRX, and CTXR HeadlinesRecent News About These CompaniesMoleculin Biotech, Inc. (NASDAQ:MBRX) Sees Large Growth in Short InterestMay 2, 2026 | americanbankingnews.comMoleculin’s Annamycin Extends Survival by More Than 60% in Metastatic Pancreatic Cancer Preclinical Models - Data Presented at AACR 2026April 24, 2026 | markets.businessinsider.comMoleculin Biotech, Inc. Reports Promising Preclinical Results for Annamycin in Pancreatic Cancer TreatmentApril 23, 2026 | quiverquant.comQMoleculin's Annamycin Extends Survival by More Than 60% in Metastatic Pancreatic Cancer Preclinical Models - Data Presented at AACR 2026April 23, 2026 | globenewswire.comMoleculin Announces Abstract Accepted for Poster Presentation at the 2026 ASCO Annual MeetingApril 21, 2026 | globenewswire.comMoleculin Biotech Stockholders Approve Warrant Share IssuanceApril 15, 2026 | tipranks.comMoleculin Releases Next CEO Corner Segment Highlighting Annamycin’s Non-Cardiotoxic ProfileApril 7, 2026 | markets.businessinsider.comMoleculin Releases Next CEO Corner Segment Highlighting Annamycin's Non-Cardiotoxic ProfileApril 7, 2026 | globenewswire.comMoleculin Biotech (MBRX) price target decreased by 13.70% to 21.42March 28, 2026 | msn.comAnalysts Offer Insights on Healthcare Companies: Moleculin Biotech (MBRX) and Achieve Life Sciences (ACHV)March 26, 2026 | theglobeandmail.comMoleculin Biotech, Inc. Prepares for Key Interim Results in Pivotal AML Trial with 40% Early Remission RateMarch 23, 2026 | quiverquant.comQMoleculin Hits 45 Subject Enrollment Milestone, Triggering Final Countdown to Mid-2026 MIRACLE Trial Data ReadoutMarch 23, 2026 | globenewswire.comMoleculin Biotech, Inc.: Moleculin Reports Full Year 2025 Financial Results and Confirms Highly Anticipated 45-Patient Interim Data Unblinding in Pivotal MIRACLE Trial On Track ...March 19, 2026 | finanznachrichten.deMoleculin Biotech Updates Investors with New Corporate PresentationMarch 19, 2026 | tipranks.comMoleculin Biotech Reports 40% Preliminary CRc Rate in First 30 Patients of MIRACLE Trial for Relapsed/Refractory AMLMarch 19, 2026 | quiverquant.comQMoleculin Reports Full Year 2025 Financial Results and Confirms Highly Anticipated 45-Patient Interim Data Unblinding in Pivotal MIRACLE Trial On Track for Mid-2026March 19, 2026 | globenewswire.comMoleculin to Present at 38th Annual ROTH ConferenceMarch 17, 2026 | globenewswire.comA Pivotal Financial Report Looms for Moleculin BiotechMarch 15, 2026 | aktiencheck.deAMoleculin Releases Next CEO Corner Segment Highlighting MIRACLE StudyMarch 11, 2026 | globenewswire.comMoleculin Biotech stock plunges after warrant exercise agreementFebruary 19, 2026 | in.investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWith Nike Shares Near a 12-Year Low, Is Now the Time to Be Brave?By Sam Quirke | April 12, 20263 Dividend Aristocrats Whose Yields Can Help Combat InflationBy Chris Markoch | April 9, 2026The War Won't Last Forever: 3 Stocks That Could Lead the RecoveryBy Bridget Bennett | April 8, 2026STMicronelectronics Sends Industrial Chips Into OverdriveBy Thomas Hughes | April 24, 2026Fastenal Stock Slips After Earnings: 5 Reasons To Buy the Dip By Thomas Hughes | April 14, 2026ENTO, MBRX, BLRX, and CTXR Company DescriptionsBioLineRx NASDAQ:BLRX$3.04 0.00 (0.00%) Closing price 05/5/2026 04:00 PM EasternExtended Trading$3.04 +0.00 (+0.16%) As of 05/5/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.Citius Pharmaceuticals NASDAQ:CTXR$0.69 -0.02 (-3.27%) Closing price 05/5/2026 04:00 PM EasternExtended Trading$0.69 +0.01 (+1.02%) As of 05/5/2026 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.Entero Therapeutics NASDAQ:ENTO$2.52 +0.01 (+0.40%) As of 05/1/2026Entero Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis. It is also involved in the development of adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients, currently under Phase 2 studies for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis; and niclosamide, an oral small molecule with anti-inflammatory inhibitor therapy, currently under Phase 2 studies for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis, as well as immune checkpoint inhibitor-associated colitis and diarrhea in metastatic cancer patients. The company was formerly known as First Wave BioPharma, Inc. and changed its name to Entero Therapeutics, Inc. in May 2024. Entero Therapeutics, Inc. was incorporated in 2014 and is based in Boca Raton, Florida.Moleculin Biotech NASDAQ:MBRX$2.49 +0.01 (+0.40%) Closing price 05/5/2026 04:00 PM EasternExtended Trading$2.50 +0.01 (+0.60%) As of 05/5/2026 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. 3 Reasons Analysts Love DexCom The Great Chip Divide: AI Chip War Pivots from Hype to Execution Atomic Dividends: Big Tech's New Energy Bet Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
